British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2020

A Rapid Update

C.H. Smith; Z.Z.N. Yiu; T. Bale; A.D. Burden; L.C. Coates; W. Edwards; E. MacMahon; S.K. Mahil; A. McGuire; R. Murphy; C. Nelson-Piercy; C.M. Owen; R. Parslew; O.A. Uthman; R.T. Woolf; L. Manounah; M.C. Ezejimofor; L.S. Exton; M.F. Mohd Mustapa


The British Journal of Dermatology. 2020;183(4):628-637. 

In This Article

Implementation Toolkit

To support implementation of the recommendations, a number of documents have been developed (see File S1: Implementation Toolkit, including the Decision Aid, in the Supporting Information). These comprise a summary of licensed indications and posology for biologic therapy (Table S1); a Decision Aid, informed by the evidence reviews, to help patients and clinicians choose the appropriate biologic therapy (Table S2); absolute effects of biological drugs at licensed doses relative to placebo (Table S3); a suggested schedule for screening and monitoring (Table S4) and a list of groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV (Table S5).